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Almost 70% of all leg ulcers have a venous component.[1](#bjd16089-bib-0001){ref-type="ref"} Occurrence of venous leg ulcers (VLUs) increases with age, with the U.K. prevalence in those \> 65 years of age being estimated at about 3%.[2](#bjd16089-bib-0002){ref-type="ref"} VLUs arise from venous valve incompetence and calf muscle pump insufficiency, which leads to venous stasis and hypertension. This results in microcirculatory changes and localized tissue ischaemia.[3](#bjd16089-bib-0003){ref-type="ref"}, [4](#bjd16089-bib-0004){ref-type="ref"} The natural history of VLUs is of a continuous cycle of healing and breakdown over decades:[5](#bjd16089-bib-0005){ref-type="ref"} VLUs are typically painful and heal slowly, resulting in an impaired quality of life (QoL), social isolation and reduced work productivity.[6](#bjd16089-bib-0006){ref-type="ref"} Treatment of this major health problem results in a considerable cost to the National Health Service (NHS): each ulcer costs up to £1981 per year;[7](#bjd16089-bib-0007){ref-type="ref"} estimated total healthcare costs are between £198 million and £400 million per year,[8](#bjd16089-bib-0008){ref-type="ref"}, [9](#bjd16089-bib-0009){ref-type="ref"} with 65% of these costs occurring in the community.[10](#bjd16089-bib-0010){ref-type="ref"}

Lower‐limb compression therapy is an established first‐line therapy for VLUs,[11](#bjd16089-bib-0011){ref-type="ref"} with approximately 50% of VLUs closing within 24 weeks.[10](#bjd16089-bib-0010){ref-type="ref"} Nevertheless, recurrence rates remain high (up to 56% within 4 years).[12](#bjd16089-bib-0012){ref-type="ref"} Furthermore, up to 30% of VLUs do not respond to compression alone, remain open after 1 year of treatment and need an average of 51 treatment visits to heal.[10](#bjd16089-bib-0010){ref-type="ref"}, [11](#bjd16089-bib-0011){ref-type="ref"}, [13](#bjd16089-bib-0013){ref-type="ref"} Therefore, it is important to develop adjunct therapies to compression, which would improve healing outcomes.

Lifestyle factors, including nutrition, exercise and smoking, are mentioned in guidelines on the management of VLUs but receive relatively little emphasis.[14](#bjd16089-bib-0014){ref-type="ref"} Exercise training might enhance ulcer healing and other aspects of health, and is routinely prescribed for other cardiovascular diseases (e.g. peripheral arterial disease and coronary artery disease).[15](#bjd16089-bib-0015){ref-type="ref"}, [16](#bjd16089-bib-0016){ref-type="ref"} In patients with VLUs, supervised calf muscle exercise has been shown to increase calf muscle pump function and improve lower‐limb haemodynamics,[17](#bjd16089-bib-0017){ref-type="ref"}, [18](#bjd16089-bib-0018){ref-type="ref"} as well as mobility and QoL.[19](#bjd16089-bib-0019){ref-type="ref"}, [20](#bjd16089-bib-0020){ref-type="ref"}, [21](#bjd16089-bib-0021){ref-type="ref"} A recent systematic review suggested further research to determine whether exercise training has an effect on ulcer healing and QoL.[22](#bjd16089-bib-0022){ref-type="ref"}

Our team recently completed 'FISCU' \[Feasibility of Implementing Supervised exercise training alongside Compression therapy in people with venous Ulceration; a National Institute for Health Research‐funded study (PB‐PG‐0213‐30029)\][5](#bjd16089-bib-0005){ref-type="ref"} to assess the feasibility of a 12‐week supervised exercise programme combining aerobic, resistance and flexibility exercises as an adjunct therapy to compression in patients with VLUs. We report on rates of screening, eligibility, recruitment, retention, outcome completion, exercise adherence and adverse events (AEs). We also report on reasons for exclusion and nonconsent, sample characteristics, the distribution and completeness of potential primary outcomes, and provide information on preliminary data on effectiveness and healthcare resource use.

Patients and methods {#bjd16089-sec-0007}
====================

A full description of methods is available in our previously published protocol paper.[5](#bjd16089-bib-0005){ref-type="ref"} The study was a two‐arm, parallel‐group, randomized controlled feasibility trial conducted in two U.K. sites (Lincoln and Sheffield). Ethics approval was granted by the NHS National Research Ethics Service, Yorkshire and the Humber (Sheffield) Committee (14/YH/0091), and all participants provided written informed consent prior to enrolment. The trial was prospectively registered (Current Controlled Trials ISRCTN10205425).

Participants {#bjd16089-sec-0008}
------------

Participants were recruited from community nursing and tissue viability teams or services, community and outpatient leg ulcer clinics, and newspaper advertisement. Inclusion and exclusion criteria are given in Table [1](#bjd16089-tbl-0001){ref-type="table-wrap"}.

###### 

Study inclusion and exclusion criteria

  Inclusion criteria                                                                                                     Exclusion criteria
  ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  At least 18 years old                                                                                                  Unsuitable for or unable to exercise (determined by clinician)
  Have at least one VLU of primarily venous aetiology (determined by clinician) with maximum diameter of at least 1 cm   Unable or unwilling to tolerate lower‐limb compression
  ABPI of at least 0·8 (recorded within the previous 3 months)                                                           Insulin‐controlled diabetes mellitus
  Able and willing to tolerate lower‐limb compression                                                                    Pregnancy
                                                                                                                         Coexisting skin conditions, vasculitis, deep venous occlusion or malignant/atypical ulceration
                                                                                                                         Require major surgery
                                                                                                                         Leg ulcer with maximum diameter \< 1 cm
                                                                                                                         Have had an ulcer at the same site within the previous 3 months
                                                                                                                         Unable or do not wish to consent to participation in the trial

VLU, venous leg ulcer; ABPI, ankle brachial pressure index.
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Randomization, allocation concealment and blinding {#bjd16089-sec-0009}
--------------------------------------------------

Following baseline assessments, participants were randomly assigned 1 : 1 to an intervention group or a control group. Participants were stratified by ulcer size (maximum ulcer diameter 1--3 cm or \> 3 cm in any direction). Outcome assessors were blinded to group allocation.

Interventions {#bjd16089-sec-0010}
-------------

All participants received standard compression therapy directed by experienced tissue‐viability nurses, following standard local practice. Patients were reviewed in clinics as considered clinically necessary, with no interference by the study team.

Participants randomized to the exercise group were invited to attend three sessions of supervised exercise each week for 12 weeks (total of 36 sessions) at one of the two study exercise training facilities (Sheffield Hallam University and University of Lincoln). For details on the exercise components see Table [S1](#bjd16089-sup-0001){ref-type="supplementary-material"} (Supporting Information).

Study schedule and assessments {#bjd16089-sec-0011}
------------------------------

During visit 1, after written informed consent had been obtained and eligibility confirmed (which included a medical examination), the following baseline measurements were recorded at one of the two research centres (Sheffield Hallam University, University of Lincoln): (i) demographic data, including age, sex and socioeconomic status; (ii) clinical history, current medications, stature, body mass, ankle and calf circumference; (iii) ulcer size; (iv) ankle brachial pressure index (ABPI; a Doppler‐determined measurement of ABPI was performed according to the procedures of Aboyans *et al*.,[23](#bjd16089-bib-0023){ref-type="ref"} unless a reading \< 3 months old could be obtained from clinical records, following the patient\'s consent); (v) baseline exercise history; (vi) health‐related QoL (HRQoL) questionnaires (EQ‐5D‐5L and VEINES‐QOL);[24](#bjd16089-bib-0024){ref-type="ref"}, [25](#bjd16089-bib-0025){ref-type="ref"}, [26](#bjd16089-bib-0026){ref-type="ref"} (vii) lower‐limb cutaneous microvascular function (methods and results reported elsewhere);[27](#bjd16089-bib-0027){ref-type="ref"} (viii) physical fitness, using three items from the Senior Fitness Test (6‐min walking test, chair sit and reach, chair sit and stand)[28](#bjd16089-bib-0028){ref-type="ref"} and ankle range of motion assessed using a bi‐plane ankle goniometer.

All participants were given a resource use diary to complete at home for the duration of the study (to conduct health economics analysis).

Participants were then randomized to one of the two groups, as described above.

At 12 weeks and 12 months, participants had the following measures and tests repeated: physical fitness, microvascular function, ulcer‐related clinical data (size, status and recurrence) and medications, body mass and HRQoL questionnaires. A copy of the resource use diary was also taken. A postal assessment involving the completion of HRQoL questionnaires was also undertaken at 6 months.

Feasibility and acceptability outcomes {#bjd16089-sec-0012}
--------------------------------------

Recruitment rates were measured as rate of invited participants who were eligible and consenting. Acceptability of allocation was assessed by examining reasons for dropout in discontinuing participants and comparing attrition rates between the two study groups. Suitability of measurement procedures was evaluated by outcome completion rates and reasons for missing data. Attrition rate was established as discontinuation of intervention and loss to follow‐up measurement for all conditions. The acceptability of the exercise programmes was assessed by using session attendance and compliance data and participant feedback via one‐to‐one semi‐structured interviews conducted with a subgroup of participants after the 3‐month follow‐up visit (detailed analysis will be presented elsewhere). The safety of exercise training was also assessed by exploring reasons for dropout from the exercise programme and the number and type of AEs that occurred in each group.

Sample size {#bjd16089-sec-0013}
-----------

Sample size calculation was based on willingness for randomization and aimed to recruit 80 participants within an 18‐month recruitment period (Table [S1](#bjd16089-sup-0001){ref-type="supplementary-material"}; see Supporting Information).

Data analysis {#bjd16089-sec-0014}
-------------

All analyses were conducted on an intention‐to‐treat basis, conducted in SPSS version 24 (IBM, Armonk, NY, U.S.A.). Missing data were reported by trial arm with description of underlying reasons.

### Baseline {#bjd16089-sec-0015}

Summary tables report all baseline variables, and clinical, fitness and patient‐reported outcome variables. Continuous variables were summarized with descriptive statistics. Frequency counts and percentages were provided for categorical data.

### Feasibility and acceptability {#bjd16089-sec-0016}

For success criteria, see Table [2](#bjd16089-tbl-0002){ref-type="table-wrap"}. Outcomes used to assess the feasibility and acceptability of key trial parameters were rates of eligibility, recruitment, retention, outcome completion, exercise adherence and AEs.[5](#bjd16089-bib-0005){ref-type="ref"} Group preference, reasons for exclusion and nonconsent, sample characteristics and the distribution of potential primary outcomes are presented.

###### 

Criteria for success/progression

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  An appropriate primary outcome variable is defined
  At least 67% of randomly assigned patients in the exercise group are compliant with the intervention (defined as at least 75% of the scheduled sessions completed as planned)
  Loss to follow‐up at 12 months is \< 20%
  Patient preferences are not so strong that they result in the conclusion that a randomized controlled trial is not a feasible design
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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### Clinical, fitness and patient‐reported outcomes {#bjd16089-sec-0017}

Descriptive statistics are presented for clinical, fitness and patient‐reported outcomes at each time point.

Economic evaluation {#bjd16089-sec-0018}
-------------------

A prospective economic evaluation was rehearsed to develop and refine the methods for a subsequent definitive trial (Appendix [S1](#bjd16089-sup-0002){ref-type="supplementary-material"}; see Supporting Information).

Results {#bjd16089-sec-0019}
=======

Figure [1](#bjd16089-fig-0001){ref-type="fig"} shows the flow of participants through the trial. Recruitment took place between July 2014 and May 2016, with all follow‐up data collection completed by May 2017. The trial was extended for 3 months to allow extra recruitment time.

![Flow of participants through the trial. HRQoL, health‐related quality of life.](BJD-178-1072-g001){#bjd16089-fig-0001}

Screening, eligibility and recruitment {#bjd16089-sec-0020}
--------------------------------------

A summary of feasibility and acceptability data is presented in Table [3](#bjd16089-tbl-0003){ref-type="table-wrap"}. All success criteria were met (e.g. 72% of participants completed all exercise sessions, loss to follow‐up was 5%, patient preference to the exercise group was 44%, whereas median ulcer healing time was chosen as the primary outcome for the definitive trial). Of 514 patients screened for participation, 109 met the eligibility criteria and 39 (24 men, 15 women) were recruited, giving eligibility and recruitment rates of 21% and 36%, respectively. Sites 1 and 2 recruited 38 and one participants, respectively. Reasons for nonconsent and exclusion are shown in Figure [1](#bjd16089-fig-0001){ref-type="fig"}.

###### 

Summary of trial feasibility and acceptability data

  Methodological issues                                                                       Findings                                                                                                             Evidence
  ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  What factors influenced eligibility and what proportion of those screened were eligible?    Tissue viability clinics see a variety of patient wounds, the majority of which are not ulcers or of venous origin   109/514 screened were eligible; the most common reasons for noneligibility were ulcer not of venous origin or other type of wound present (*n *=* *206); the main reasons for nonconsent were mainly of social origin (e.g. work commitments or difficulty travelling; *n *=* *52)
  Was recruitment successful?                                                                 Recruitment was slower than anticipated                                                                              39 participants were recruited within a 21‐month period
  Were eligible patients recruited?                                                           Conversion rate to recruitment was within our primary targets                                                        39/109 (36%) eligible participants were recruited in the study
  Were participants successfully randomized and did randomization yield equality in groups?   Randomization process worked well                                                                                    Similar sized groups, well‐balanced on stratification and most other variables; however, QoL scores were higher at baseline in the exercise group
  Were blinding procedures adequate?                                                          Blinding of outcome assessors and ulcer healing assessments worked well                                              Two different assessors were used at follow‐up sessions. No discussions were reported between participants and assessors on their study experience during follow‐up sessions. Assessment of digital ulcer photographs was completed by a team member unaware of the association between study ID numbers and group allocation
  Did participants adhere to the intervention?                                                We experienced a very high attendance rate                                                                           13/18 (72%) of the exercise group participants attended 100% of the scheduled exercise sessions; 512/648 (79%) of the scheduled sessions were completed
  Was the intervention acceptable to the participants?                                        Qualitative and quantitative data from exercise participants suggest that the intervention was acceptable            Of the 27 participants who expressed a preference for a specific group before allocation (12 of the study participants did not express a preference), 17 (69% among those expressing preference; 44% among all) preferred exercise. Patient interviews (reported elsewhere) have also suggested a high degree of satisfaction
  Was the intervention safe?                                                                  Our preliminary safety data appear favourable                                                                        Two nonserious AEs (excess fluid discharge from ulcer) were noted during the study; no bandaging was affected during the exercise sessions
  Were outcome assessments completed?                                                         Outcome completion rates were very high                                                                              See '[Results](#bjd16089-sec-0019){ref-type="sec"}' section
  Was it possible to calculate intervention and healthcare utilization costs?                 Yes                                                                                                                  Cost of exercise programme: £610·22 per participant. Total costs per participant were £2412·2 (including out‐of‐pocket expenses) and £1537·10 for control and exercise group patients, respectively
  Was retention to the study good?                                                            Retention was very high                                                                                              Retention rate 95%
  Did all components of the protocol work together?                                           From the point that the recruitment procedures were modified, components had strong synergy                          There were no major difficulties identified in the various processes and the researchers' ability to implement them. For example, if participants were recruited, there was excellent collaboration between the care and the research team in regards to data capture (e.g. tracing, ulcer photography)
  Was an appropriate outcome defined for the definitive trial?                                Yes                                                                                                                  Based on our study and previous research experience, a reduction in ulcer healing time appears to be the most appropriate outcome for the definitive trial

QoL, quality of life; AE, adverse event.
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Group allocation, group preference and participant characteristics {#bjd16089-sec-0021}
------------------------------------------------------------------

Eighteen participants were allocated to exercise and 21 to usual care. Seventeen (63%) of 27 participants expressed a preference for exercise (12 expressed no preference). Participant characteristics at baseline are shown in Table [4](#bjd16089-tbl-0004){ref-type="table-wrap"}; the groups were well balanced for most variables except QoL.

###### 

Summary of baseline demographics

  Baseline characteristics                                     Intervention (*n *=* *18)   Control (*n *=* *21)   Combined (*n *=* *39)
  ------------------------------------------------------------ --------------------------- ---------------------- -----------------------
  Male                                                         9 (50)                      14 (67)                23 (59)
  Mean ± SD age (y)                                            65·4 ± 14·9                 61·9 ± 10·9            63·5 ± 12·8
  Working                                                      8 (44)                      6 (29)                 14 (36)
  White ethnicity                                              17 (94)                     21 (100)               38 (98)
  Mean ± SD body mass (kg)                                     102·1 ± 29·4                104·9 ± 24·3           103·6 ± 26·5
  Mean ± SD SBP (mmHg)                                         143 ± 20                    140 ± 18               141 ± 19
  Mean ± SD DBP (mmHg)                                         79 ± 10                     84 ± 13                81 ± 12
  Mean ± SD HR (bpm)                                           72 ± 13                     69 ± 11                70 ± 12
  Smoking status                                               4 (22)                      5 (24)                 9 (23)
  Mean ± SD alcohol consumption (units weekly)                 8 ± 13                      9 ± 14                 8 ± 13 
  Key medications                                                                                                 
  Antiplatelet/anticoagulant                                   7 (39)                      5 (24)                 12 (31)
  Statin                                                       3 (17)                      5 (24)                 8 (21)
  ACE inhibitor                                                1 (6)                       1 (5)                  2 (5)
  Beta blocker                                                 3 (17)                      6 (29)                 9 (23)
  Calcium channel blocker                                      1 (6)                       2 (10)                 3 (8)
  Diuretic                                                     4 (22)                      3 (14)                 7 (18)
  Comorbidities                                                12 (67)                     16 (76)                27 (69)
  Hypertension                                                 7 (39)                      4 (19)                 11 (28)
  History of other CVD                                         1 (6)                       8 (38)                 9 (23)
  Noninsulin‐dependent diabetes                                4 (22)                      4 (19)                 8 (21)
  History of cancer                                            2 (11)                      1 (5)                  3 (8)
  Hypercholesterolaemia                                        1 (6)                       2 (10)                 3 (8)
  Ulcer‐related                                                                                                   
  Had ulcer before                                             11 (61)                      14 (67)                25 (64)
  Mean ± SD duration of reference ulcer (months)               12·7 ± 19·9                  7·1 ± 8·1              7·9 ± 14·8
  Mean ± SD time since diagnosis of reference ulcer (months)    8·9 ± 13·7                 6·1 ± 8·0              7·4 ± 10·9
  Had ulcer at same site (\> 3 months previously)               3 (17)                      3 (14)                 6 (15)
  Median (range) ulcer length (cm)                             2·6 (1·2 to 13·5)           2·8 (1·2 to 11·8)      2·7 (1·2 to 13·5)
  Median (range) ulcer width (cm)                              1·9 (0·9--10·1)             1·9 (1·1--6·5)         1·9 (0·9--10·1)
  Median (range) ulcer area (cm^2^)                            4·9 (1·9--136·4)            5·7 (1·3--56·6)        5·0 (1·3--136·4)
  Mean ± SD ABPI                                               1·0 ± 0·1                   1·1 ± 0·2              1·1 ± 0·2
  Physical activity and fitness                                                                                   
  Walking with difficulty                                      8 (44)                      10 (48)                18 (46)
  No walking                                                   5 (28)                      7 (33)                 12 (31)
  Walking \< 1 h                                               3 (17)                      5 (24)                 8 (21)
  Walking 1--3 h                                               6 (33)                      5 (24)                 11 (28)
  Walking ≥ 3 h                                                4 (22)                      4 (19)                 8 (21)
  Exercise/physical activity other than walking                14 (78)                     16 (76)                30 (77)

Data are *n* (%) unless otherwise indicated. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per min; ABPI, ankle brachial pressure index.
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Retention {#bjd16089-sec-0022}
---------

Retention rate was 95%. Two of 39 participants formally left the study; one from the exercise group for ulcer pain before the 3‐month assessment and one from the control group for nonulcer‐related health reasons before the 6‐month assessment. All others completed all assessment sessions. Four participants withdrew from exercise training due to family commitments and nonulcer‐related health reasons.

Exercise attendance and safety data {#bjd16089-sec-0023}
-----------------------------------

Of the 18 exercise participants, 13 (72%) completed all sessions; overall session completion rate was 79% (*n *=* *512/648). No bandage slippage/misplacement was detected during exercise sessions. We observed two exercise‐related AEs (both excessive discharge from the ulcer). Actions taken included the removal of resistance exercises and postponement of exercise sessions.

Physical function and body mass {#bjd16089-sec-0024}
-------------------------------

Participants in the exercise group showed higher mean values at 3 months in all tests (Table [5](#bjd16089-tbl-0005){ref-type="table-wrap"}). Results stabilized at 12 months for all tests except plantar flexion. Weight reduction was modest for the exercise group in relation to the baseline (mean ± SD 103·9 ± 24 kg at baseline vs. 99·8 ± 28·4 kg at 12 months). In contrast there was an increase in weight in the control group (mean ± SD 102·6 ± 25·6 kg vs. 105·7 ± 25·2 kg at 12 months).

###### 

Physical fitness/function indices

                                     Exercise group   Control group                                             
  ---------------------------------- ---------------- --------------- ------------- ------------- ------------- -------------
  6‐min walk distance (m)            276 ± 100        290 ± 123       291 ± 122     280 ± 141     284 ± 138     273 ± 146
  Chair sit‐to‐stand (repetitions)   8 ± 4            10 ± 4          9 ± 4         9 ± 4         9 ± 4         8 ± 4
  Chair sit‐and‐reach (score)        −6·4 ± 11·4      2·6 ± 16·0      2·2 ± 11·8    −2·8 ± 13·6   −0·8 ± 11·3   −1·7 ± 11·9
  Plantar flexion (°)                18·7 ± 21·0      22 ± 15·9       17·6 ± 12·8   15·1 ± 9·1    19·0 ± 22·3   14·7 ± 9·4
  Dorsiflexion (°)                   20·5 ± 14        22·9 ± 14·8     18·9 ± 15·8   20·3 ± 16·5   18·7 ± 24·2   17·4 ± 15·3
  Ankle range of movement (°)        39·2 ± 19·9      44·9 ± 21·3     36·6 ± 20·8   35·4 ± 19·7   37·7 ± 43·2   32·1 ± 18·9

Data are mean ± SD.
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Ulcer‐related data {#bjd16089-sec-0025}
------------------

Median ulcer size was similar between groups at 12 months (Table [6](#bjd16089-tbl-0006){ref-type="table-wrap"}), but healing rate was higher in the intervention group (83% vs. 60%), with shorter median (range) ulcer healing time \[13 (3·9--52) vs. 34·7 (4·3--52) weeks\]. Recurrence rates were low in both groups (two in the intervention group, one in the control group).

###### 

Ulcer‐related data

                                                 Exercise           Control                                                                                
  ---------------------------------------------- ------------------ ------------ ------------ -------------- ----------------- --------------- ----------- ----------------
  Median (range) ulcer size                                                                                                                                
  Length (cm)                                    2·6 (1·2--13·5)    0 (0--5)     NA           0 (0--5·5)     2·8 (1·2--11·8)   1·3 (0--10·2)   NA          0 (0--14)
  Width (cm)                                     1·9 (0·9--10·1)    0 (0--6·5)   NA           0 (0--3·4)     1·9 (1·1--6·5)    1 (0--7·7)      NA          0 (0--10·5)
  Area (cm^2^)                                   4·9 (1·9--136·4)   0 (0--26)    NA           0 (0--18·7)    5·7 (1·3--56·6)   1·5 (0--78·5)   NA          0 (0--147)
  Whether healed, *n* (%)                                           9/17 (53)    11/17 (65)   14/17 (83)                       3/21 (14)       8/20 (40)   12/20 (60)
  Median (range) time of ulcer healing (weeks)                                                13 (3·9--52)                                                 34·7 (4·3--52)
  Reoccurrence of ulcer, *n* (%)                                    0/17 (0)     1/17 (6)     2/17 (12)                        0/20 (0)        2/17 (12)   1/19 (5)

NA, not available.
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Health‐related quality of life {#bjd16089-sec-0026}
------------------------------

Participants in the intervention group started the study with a higher EQ‐5D utility score than the control group (Table [7](#bjd16089-tbl-0007){ref-type="table-wrap"}; mean ± SD 0·8022 ± 0·17 vs. 0·6010 ± 0·35). This difference was maintained throughout the study. A similar difference was observed with EQ visual analogue scale, VEINES‐QOL (overall score and symptom score) and pain score, although for VEINES‐QOL and pain score, the difference between groups was increased from 3 months onwards.

###### 

Summary of health status, disease‐specific quality of life and pain data

                             Exercise        Control                                                                                         
  -------------------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  EQ‐5D‐5L utility score     0·8022 ± 0·17   0·8567 ± 0·15   0·8147 ± 0·21   0·7874 ± 0·28   0·6010 ± 0·35   0·5698 ± 0·42   0·5740 ± 0·40   0·5825 ± 0·41
  EQ‐VAS score               69·03 ± 15·13   75·35 ± 15·38   71·47 ± 21·34   75·53 ± 20·37   57·43 ± 19·84   64·33 ± 22·74   58·70 ± 26·21   56·20 ± 27·58
  VEINES‐QoL: main           53·68 ± 24·62   69·53 ± 26·13   67·49 ± 27·75   67·23 ± 29·86   42·65 ± 24·70   47·24 ± 29·57   51·79 ± 33·62   52·46 ± 34·81
  VEINES symptom subdomain   62·03 ± 26·52   75·18 ± 24·76   73·24 ± 26·26   73·41 ± 31·73   53·17 ± 28·82   54·60 ± 32·11   58·13 ± 30·05   58·53 ± 33·58
  Pain score                 24·44 ± 27·3    15·9 ± 27·7     16·5 ± 28·4     7·9 ± 22·8      30·95 ± 31·6    22·1 ± 32·8     28·0 ± 36·3     30·5 ± 36·6

Data are mean ± SD.
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Health economic data {#bjd16089-sec-0027}
--------------------

There were no missing data for procedure costs. Mean exercise intervention costs per participant was £610·22, including staff time, room hire and patient reimbursement. Mean total NHS costs (based on NHS National Tariff Schedules and calculated based on visits and usage of NHS resources) were calculated as £813·27 for the exercise and £2298·57 for the control group.

Personal costs were calculated using a diary with 'out‐of‐pocket' expenses being estimated at £113·63 and £174·58 for the exercise and control groups, respectively.

The mean 'per patient' cost savings to the NHS from the exercise intervention was £875·08. Similarly, the 'per patient' less 'out‐of‐pocket' expenses to participants, as a result of participation in exercise intervention, was £60·95. The combined per 'per patient' mean total cost saving was £936·03 (Table [8](#bjd16089-tbl-0008){ref-type="table-wrap"} and Appendix [S1](#bjd16089-sup-0002){ref-type="supplementary-material"}; see Supporting Information).

###### 

Summary of annual costs to the National Health Service (NHS), out‐of‐pocket (OOP) expenses of treatment and intervention study cost by group

  Cost type                               Total (£)   Mean Per patient (£)                                  
  --------------------------------------- ----------- ---------------------- ----------- -------- --------- ---------
  NHS healthcare professional             12 724·00   34 573·00              47 297·00   748·47   1646·33   1244·66
  A&E                                     0           2110·00                2110·00     0        100·48    55·53
  Inpatient care                          0           9365·00                9365·00     0        445·95    246·45
  Diagnostic tests                        257·00      746·00                 1003·00     15·12    35·52     26·39
  Medicine (free prescriptions)           844·60      1476·00                2320·60     49·68    70·29     61·07
  Total cost to NHS                       13 825·60   48 270·00              62 095·60   813·27   2298·57   1634·09
  Cost to patients                                                                                          
  Travel                                  1081·66     2341·68                3423·34     63·63    111·51    90·09
  Medicine                                229·10      413·44                 642·54      13·48    19·69     16·91
  Equipment                               621·00      911·00                 1532·00     36·53    43·38     40·32
  Total OOP expenses                      1931·76     3666·12                5597·88     113·63   174·58    147·31
  Intervention study cost                                                                                   
  Exercise intervention delivery          10 984·00   NA                     10 984·00   610·22             610·22
  Including study outcome measures cost   14 051·17   3255·17                17 306·33   780·62   155·01    455·43

A&E, Accident and Emergency; NA, not applicable.
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Discussion {#bjd16089-sec-0028}
==========

We successfully assessed several feasibility study aspects, including recruitment, baseline and follow‐up measurements, as well as the feasibility and preliminary effectiveness of a supervised exercise programme for people with VLUs. Our main finding was that the study procedures were feasible and acceptable.

The feasibility and acceptability of using a supervised exercise regime as an adjunct therapy to compression therapy had been an area of uncertainty prior to this study. Indeed, during the preliminary study stages, such a notion was met with scepticism by some clinicians and patients, who believed that exercise may be either inappropriate or harmful, and may delay rather than promote healing -- an attitude that has also been documented in the literature.[29](#bjd16089-bib-0029){ref-type="ref"}, [30](#bjd16089-bib-0030){ref-type="ref"} Nevertheless, the majority of the eligible patients had a positive attitude towards undertaking exercise in addition to following a therapeutic pathway based on compression therapy. This was irrespective of whether they consented to take part and reasons for nonparticipation will help make the programme more accessible (i.e. by choosing appropriate venues). Our feasibility data show few AEs, with no bandage misplacement or slippage incidents, one of the biggest concerns of collaborating clinicians.

Exercise attendance was 79%, with 72% of participants completing all sessions. This is high considering that many participants were old, frail and had no previous exercise experience. This was achieved without employing any specific adherence‐enhancing components or provision of behavioural change support, which could have potentially improved attendance rates and the effect of the intervention even further.[31](#bjd16089-bib-0031){ref-type="ref"} This suggests great interest and self‐motivation from our participants, which will be a decisive factor for the success of a definitive trial and any wider roll‐out of the intervention. However, despite our success, it is our plan to incorporate cognitive--behavioural strategies as part of any future trial to optimize exercise adherence and increase any potential, positive effect.

With regard to practicality our intervention was primarily delivered within a university setting, at some distance from the clinics in which our participants were treated. The high attendance rate suggests that this did not have a negative impact on the outcome, although it may have affected recruitment rate. Recruitment rate may be improved in the definitive trial, where 12‐week exercise referral schemes will be utilized for the intervention delivery.[32](#bjd16089-bib-0032){ref-type="ref"} Delivery with an option of times in community‐based venues increases accessibility but comes with a number of challenges (as adherence and success varies);[33](#bjd16089-bib-0033){ref-type="ref"} recent research suggests that these schemes can offer QoL and physical activity gains.[34](#bjd16089-bib-0034){ref-type="ref"}

Our findings support the feasibility of using diaries to collect economic data on patients' usage of NHS resources, healthcare visits, prescriptions and out‐of‐pocket expenses. The findings suggest potential savings to both the NHS (£875·08 per patient) and patients (£60·95 reduction in out‐of‐pocket expenses). Nevertheless, as our analysis was purely descriptive, an appropriate health economics analysis in the definitive trial will provide greater certainty regarding cost‐effectiveness.

Overall, no major difficulties were identified in the design or implementation of trial procedures. For example, the blinding procedures ran as intended, the rates of retention and outcome completion (including the 6‐month postal assessment) was very good, and from a point onwards there was an excellent communication between clinical and research teams, which allowed smooth recruitment. There was an imbalance between groups in the EQ‐5D‐5L data; this did not affect the success of our study but may need to be considered in planning the definitive trial.

Designing, setting up and managing a definitive, multicentre study has other challenges besides recruitment rate, data collection and exercise delivery. One important issue is the recruitment of a sufficient number of sites which will: (i) deliver the required number of participants; (ii) have experienced clinicians to act as local Principal Investigators; (iii) have dedicated tissue viability services, which will support and promote the study; and (iv) have a good communication level between exercise deliverers, tissue viability clinics, local stakeholders (e.g. NHS Trusts) and the main research team. It is therefore advisable that a clinical trials unit is utilised to safeguard data quality and guarantee database management, in addition to costing dedicated personnel (e.g. a trial coordinator and a trial manager) for day‐to‐day study management and involving experienced research sites in previous, similar studies (which would safeguard a consistent delivery of the trial protocol).

Our findings support the feasibility and acceptability of both the supervised exercise programme in conjunction with compression therapy and the study procedures and all our success criteria were met.[5](#bjd16089-bib-0005){ref-type="ref"} In addition, our results suggest that there may be significant potential benefit in healing rates and that, if this were confirmed in a full trial, the introduction of supervised exercise for VLU may well also save costs for the NHS. The next step will be the design and implementation of an appropriately powered, multicentre trial, which is required to provide answers to the questions of the clinical and cost‐effectiveness of the intervention.
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